H. Johannsdottir

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology · 2012 · 371 citations

Second-line Treatment, Oncology, Cancer Management +6

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Silvia Novello, Julien Mazières, In‐Jae Oh et al. · Annals of Oncology · 2018 · 336 citations · Full text

Host Cell Factors and Functions Involved in Vesicular Stomatitis Virus Entry

H. Johannsdottir, Roberta Mancini, Jürgen Kartenbeck et al. · Journal of Virology · 2008 · 207 citations

Virus Structure, Molecular Virology, Pathogenesis +14

Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors

H. Johannsdottir, Göran Jönsson, Guðrún Jóhannesdóttir et al. · International Journal of Cancer · 2006 · 65 citations · Full text

Breast Oncology, Cytogenetics, Genetics +16

Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin

Gudbjorg R Sigurjonsdottir, Simon Stacey, Gísli H. Halldórsson et al. · JNCI Journal of the National Cancer Institute · 2018 · 37 citations · Full text